Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/201454
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Villa Crespo, Lorena | - |
dc.contributor.author | Podlipnik, Sebastian | - |
dc.contributor.author | Anglada, Natalia | - |
dc.contributor.author | Izquierdo, Clara | - |
dc.contributor.author | Giavedoni, Priscila | - |
dc.contributor.author | Iglesias, Pablo | - |
dc.contributor.author | Dominguez, Mireia | - |
dc.contributor.author | Aya, Francisco | - |
dc.contributor.author | Arance, Ana | - |
dc.contributor.author | Malvehy, Josep | - |
dc.contributor.author | Puig, Susana | - |
dc.contributor.author | Carrera, Cristina | - |
dc.date.accessioned | 2023-08-02T11:13:06Z | - |
dc.date.available | 2023-08-02T11:13:06Z | - |
dc.date.issued | 2022-02-27 | - |
dc.identifier.issn | 2072-6694 | - |
dc.identifier.uri | http://hdl.handle.net/2445/201454 | - |
dc.description.abstract | Immune-related adverse events (irAEs) are frequent and could be associated with improved response to immune checkpoint inhibitors (ICIs). A prospective cohort of advanced melanoma patients receiving ICI as first-line therapy was retrospectively reviewed (January 2011-February 2019). A total of 116 of 153 patients presented with at least one irAE (75.8%). The most frequent irAEs were dermatological (derm irAEs, 50%), asthenia (38%), and gastrointestinal (29%). Most irAEs appeared within the first 90 days, while 11.2% appeared after discontinuation of the therapy. Mild grade 1-2 derm irAEs tended to appear within the first 2 months of therapy with a median time of 65.5 days (IQR 26-139.25), while grade 3-4 derm irAEs appeared later (median 114 days; IQR 69-218) and could be detected at any time during therapy. Only derm irAE occurrence was related to improved survival (HR 6.46). Patients presenting derm irAEs showed better 5-year overall survival compared to those with no derm irAEs (53.1% versus 24.9%; p < 0.001). However, the difference was not significant when adjusting for the duration of therapy. In conclusion: the timeline of immune-related-AEs differs according to the organ involved. The (apparent) improved survival of patients who present derm AEs during immunotherapy could be partially explained by longer times under treatment. | - |
dc.format.extent | 11 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/cancers14051237 | - |
dc.relation.ispartof | Cancers, 2022, vol. 14, num. 5, p. 1237 | - |
dc.relation.uri | https://doi.org/10.3390/cancers14051237 | - |
dc.rights | cc by (c) Villa Crespo, Lorena et al., 2022 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) | - |
dc.subject.classification | Melanoma | - |
dc.subject.classification | Immunoglobulines | - |
dc.subject.other | Melanoma | - |
dc.subject.other | Immunoglobulins | - |
dc.title | Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2023-07-03T09:05:45Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.idimarina | 9300294 | - |
dc.identifier.pmid | 35267545 | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Timeline of Adverse Events during Immune Checkpoint Inhibitors_Cancers.pdf | 2.04 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License